Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
A New Era in Melanoma Treatment: Combination Therapies and Molecular Precision
This week we explore the latest breakthroughs in melanoma care — from the game-changing results of the RELATIVITY-047 study to the impact of precision profiling in the Tumor Profiler project. Discover how new combination therapies, biomarker insights, and advances in TIL and tebentafusp treatments are improving survival rates while reducing toxicity. Tune in to learn why this might be the most transformative moment yet in the fight against melanoma.
Bibliography
- Lipson et al. (2025). Four-year update from the RELATIVITY-047 trial: Nivolumab plus relatlimab in advanced melanoma. Eur J Cancer.
- Miglino et al. (2025). Multi-omics tumor profiling to guide melanoma treatment: Insights from the Tumor Profiler Consortium. Nat Med.
- Sikorski et al. (2025). Tumor microenvironment characteristics and clinical relevance in melanoma. Int J Mol Sci.
- Virazels et al. (2025). TNF signature and response to immune checkpoint inhibitors in advanced melanoma: Results from the MELANFα study. Int J Cancer.
- Verdegaal et al. (2025). Effective TIL therapy in checkpoint-resistant melanoma without lymphodepletion, using IFNα. Clin Cancer Res.
- AlBarakat et al. (2025). Tebentafusp in uveal melanoma: Efficacy and safety from a systematic review and meta-analysis. Asian Pac J Cancer Prev.
- Chen et al. (2025). Role of matrix metalloproteinases in uveal melanoma progression. Eur J Med Res.
